Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:38:28.027Z.
Calculation as of: 2026-10-06T16:38:28.027Z.
Quote observation: 2026-10-06T16:32:55.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 733e4da94f9494cd21c7af02f5120fd8528014c079e3dffba0957966aae51245
PE RATIO
N/A
Market Cap
$17.19M
PE Ratio
N/A
TTM Avg
29275707116178676.00
3Y Avg
6105628756850110.00
5Y Avg
6105628756850110.00
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NextCure, Inc. (NXTC) | $18.95M | N/A | N/A | N/A | N/A |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.86M | N/A | 2.38 | 2.38 | 2.38 |
| P3 Health Partners Inc. (PIII)vs › | $18.74M | N/A | N/A | N/A | N/A |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.60M | N/A | N/A | N/A | N/A |
| Actuate Therapeutics Inc (ACTU)vs › | $19.72M | N/A | N/A | N/A | N/A |
| Cosmos Health Inc. (COSM)vs › | $17.82M | N/A | 49.08 | 49.08 | 49.08 |
| PAVmed Inc. (PAVM)vs › | $17.65M | N/A | 0.60 | 0.60 | 0.60 |
| Lipocine Inc. (LPCN)vs › | $17.19M | N/A | 29275707116178676.00 | 6105628756850110.00 | 6105628756850110.00 |
| Quantum BioPharma Ltd. (QNTM)vs › | $20.80M | N/A | N/A | N/A | N/A |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.01M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$5.25
Forward EPS (Est.)
$-6.34
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
